SITE MAP   |   CAREERS   |   CONTACT   |   
Investors and Media
Zalicus is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. Zalicus has a portfolio of proprietary product candidates targeting pain, including Z944, a T-type calcium channel modulator for chronic and acute pain and our Nav 1.7 channel modulator program for chronic or acute pain. We have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. Zalicus applies its expertise in the discovery and development of selective ion channel modulators and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease.
ZLCS (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.38 (4.69%)
Data as of 08/15/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
06/25/14Zalicus and Epirus Agree Zalicus Stockholders to Own 19% of Combined Company Post-MergerPrinter Friendly Version
06/18/14Zalicus Licenses Sodium Channel Pain Modulation ProgramPrinter Friendly Version
06/02/14Zalicus Announces Closing of cHTS Service Business Sale to Horizon Discovery GroupPrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.